Ucb SA

Ucb SA has a fully diluted share count of 190,361,362 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and returns are not yet quantified in the valuation snapshot, and no industry_config preferred metrics are available for comparison. This suggests a need for further data to evaluate Ucb SA's performance relative to its peers in the Pharmaceuticals industry. Ucb SA's revenue concentration by segment and geography is not disclosed in the available data. Without segmental or geographic revenue breakdowns, it is not possible to assess the company's exposure to specific markets or product lines. The company's growth trajectory is not quantified in the outlook, and no numeric deltas are provided for the current or next fiscal year. Analysts have issued a mean price target of 283.05 EUR and a median price target of 290.00 EUR, with a mean recommendation of 2.26 (1=strong buy, 5=strong sell). Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. The dilution risk is currently low, with no dilution potential from basic shares outstanding. No adjustments have been applied to the valuation metrics, and no specific risk factors are cited in the risk assessment. Recent events and filings are not detailed in the available data. Analysts have issued a range of price targets from 212.00 EUR to 340.00 EUR, with 3 strong-buy, 14 buy, and 4 hold recommendations.